Asset sale Announced

Dimerix acquisition of MTX652

US$292m consideration

Announced Jul 2026 (approx.)

Advisers

MTX652

Target

Financial adviser

Dimerix

Acquirer

Not disclosed

Target
MTX652
Acquirer
Dimerix
Seller
Mission Therapeutics
Target based in
United Kingdom (unverified)
Buyer based in
Australia
Seller based in
United Kingdom
Sector
Biotech
Tags
Biotech, Drug Development

In the league tables

Similar deals

All biotech deals →

Sources

Suggest a correction

A missing adviser, a wrong role or a different outcome. A link to a public source helps.